Analyst Cory Kasimov works at JPMORGAN and is focused on the Healthcare sector with 328 price targets and ratings documented since 2012 spanning on 22 stocks. Analyst's average stock valuation to be materialised ratio is 68.85% with an average time for price targets to be met of 271.05 days.
Most recent stock forecast was given on GBT, Global Blood Therapeutics, Inc at 28-Jun-2022.
Cory Kasimov best performing recommendations are on EDIT (EDITAS MEDICINE, INC).
The best stock recommendation documented was for CLVS (CLOVIS ONCOLOGY, INC) at 10/31/2018. The price target of $16 was fulfilled within 7 days with a profit of $4.37 (37.58%) receiving and performance score of 53.68.
Average potential price target upside